# Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.

> **NCT00226993** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Stanford University**

## Conditions studied

- Mycosis Fungoides

## Interventions

- **DRUG:** CPG 7909

## Key facts

- **NCT ID:** NCT00226993
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2005-03
- **Primary completion:** 2006-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00226993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00226993, "Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00226993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*